Product Description
Smeiglutide Injection (Novo Nordisk) is a novel long-acting glucagon-like peptide-1 (GLP-1) analogue from Novo Nordisk for the control of blood glucose in adults with type 2 diabetes who have received metformin and/or sulfonylureas in addition to diet control and exercise.
And reduce the risk of major cardiovascular adverse events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type
Ingredients:
2 diabetes with cardiovascular disease.
Active ingredient: Smeiglutide (human glucagon-like peptide-1 (GLP-1) analogue produced by saccharomyces cerevisiae cells through genetic recombination technology). The 1ml injection contains 1.34mg of Smeiglutide. Each prefilled injection pen contains 2mg of Smerglutide in 1.5ml solution.
Chemical name: Nε26[(S)- (22, 40-dicarboxylic acid -10, 19, 24-trioxy-3, 6, 12, 15-tetraoxy-9, 18, 23-triazazane -1-acyl)][Aib8, Arg34]GLP-1- (7-37) peptide [2]
Chemical structure formula:
Molecular formula: C187H291N45O59
Molecular weight: 4113.58g/mol
Excipients: disodium hydrogen phosphate dihydrate, propylene glycol, phenol, hydrochloric acid (for regulating pH value), sodium hydroxide (for regulating pH value) and water for injection. This product uses phenol as a bacteriostatic agent, 0.550g phenol is added to 100ml of this product.